Main Menu

Yearly Archives: 2016

/2016

‘All in’ for Clinical Care Excellence

Caring, Compassionate, Skilled. These adjectives describe nurses that every patient wants at the bedside. They also apply to Holly Langster, the Myeloma Institute’s director of clinical operations, who joined our team in July. An advanced practice nurse with more than 20 years of nursing experience, Langster holds a Doctor of Nursing Practice, a degree that [...]

December 15th, 2016|Fall 2016, Myeloma Magazine, Uncategorized|

UAMS’ van Rhee Receives Award for Castleman Disease

November 17th, 2016|News, Uncategorized|

Blog Gives Multiple Myeloma Patient Way to Share

Oct. 27, 2016 | Sean Murray of Kimberling City, Missouri, was working a stressful job in November 2008. His project list was long and deadlines were coming due. So, yes, he noticed the pain in the upper middle part of his back. But the 49-year-old figured it was a pinched nerve or a pulled muscle [...]

November 1st, 2016|News, Uncategorized|

“I owe my life to UAMS.”

This video was filmed in 2011 when David Fajgenbaum was in in his third year of medical school. Since then, Fajgenbaum has had two more life-threatening relapses, but he is currently in his longest remission since becoming ill with HHV-8-negative multicentric Castleman disease. Fajgenbaum, MD, MBA, MSc, is now an assistant professor of Medicine in [...]

October 13th, 2016|News, Uncategorized|

From the Director

Dear Readers, The world of myeloma research is undergoing exciting advances that are changing the landscape of diagnosis and therapeutic interventions. With new drug development, creative combinations of drugs, increased understanding of how the body’s immune system can be harnessed, and the ability to define each patient’s disease at the molecular level, we can now [...]

May 6th, 2016|Myeloma Magazine, Spring 2016, Uncategorized|

From the Editor

Welcome to the inaugural issue of Myeloma, the journal of the Myeloma Institute at the University of Arkansas for Medical Sciences. The goal of Myeloma is to provide timely updates about progress in clinical treatment and research advances, as well as stories and information of general interest. As a world leader in myeloma and related [...]

May 6th, 2016|Spring 2016, Uncategorized|

The Myeloma’s Institute Approach for Advances and a Cure

Dr. Frits van Rhee visits with a patient prior to his infusion. Innovative translational research has been at the core of the UAMS myeloma program since its inception in 1989. Translational research is research that bridges basic science with developments in clinical care.  Breakthroughs in the laboratory are translated rapidly into clinical care [...]

May 6th, 2016|Myeloma Magazine, Spring 2016, Uncategorized|

Distilling Excellence

Commitment to excellence… focus on customers… ongoing improvement… ingenuity and resourcefulness… treating others with dignity and respect… nimbly adapting to new developments. These are values that help an organization perform at its best and endure. They have guided Heaven Hill Distilleries throughout its 80-year history and have ensured its success. America’s largest family-owned and operated [...]

May 6th, 2016|Myeloma Magazine, Spring 2016, Uncategorized|

New Clinical Trials

A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone, in Relapsed Multiple Myeloma Patients UARK 2015-03 Principal Investigator: Faith Davies, M.D. ClinicalTrials.gov Identifier: NCT02578121 The primary objective is to determine the efficacy of ixazomib when combined with pomalidomide and dexamethasone, in terms of overall response rate in patients with relapsed myeloma. [...]

May 6th, 2016|Myeloma Magazine, Spring 2016, Uncategorized|

Advancing Cure with CyTOF Technology

Based on our years of experience in the research and treatment of myeloma and related diseases, we are confident that personalized approaches to treatment hold the best promise for a cure. The ability to customize treatment demands comprehensive knowledge about the nuances of each individual’s disease. With CyTOF technology, we will be able to [...]

May 6th, 2016|Myeloma Magazine, Spring 2016, Uncategorized|